Mulpleta is now available in the US for the treatment of thrombocytopenia - Shionogi.
Shionogi & Co., Ltd. announced that Mulpleta (lusutrombopag), a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure, is now available throughout the United States.
Shionogi has developed Mulpleta Assist, a support center for physicians and patients, to help make Mulpleta easier to access and ensure that patients receive Mulpleta before their procedure.To learn more about Mulpleta or Mulpleta Assist, please visit www.Mulpleta.com.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.